<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Children (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Children (Basel)</journal-id><journal-id journal-id-type="publisher-id">children</journal-id><journal-title-group><journal-title>Children</journal-title></journal-title-group><issn pub-type="epub">2227-9067</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29558389</article-id><article-id pub-id-type="pmc">5867502</article-id><article-id pub-id-type="doi">10.3390/children5030043</article-id><article-id pub-id-type="publisher-id">children-05-00043</article-id><article-categories><subj-group subj-group-type="heading"><subject>Opinion</subject></subj-group></article-categories><title-group><article-title>Pediatric Melanoma and Drug Development</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rose</surname><given-names>Klaus</given-names></name><xref ref-type="aff" rid="af1-children-05-00043">1</xref><xref rid="c1-children-05-00043" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Grant-Kels</surname><given-names>Jane M.</given-names></name><xref ref-type="aff" rid="af2-children-05-00043">2</xref></contrib></contrib-group><aff id="af1-children-05-00043"><label>1</label>klausrose Consulting, Pediatric Drug Development &#x00026; More, 4125 Riehen, Switzerland</aff><aff id="af2-children-05-00043"><label>2</label>Department of Dermatology, University of Connecticut Health Center, Farmington, CT 06030, USA; <email>grant@uchc.edu</email></aff><author-notes><corresp id="c1-children-05-00043"><label>*</label>Correspondence: <email>klaus.rose@klausrose.net</email></corresp></author-notes><pub-date pub-type="epub"><day>20</day><month>3</month><year>2018</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2018</year></pub-date><volume>5</volume><issue>3</issue><elocation-id>43</elocation-id><history><date date-type="received"><day>19</day><month>2</month><year>2018</year></date><date date-type="accepted"><day>14</day><month>3</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; 2018 by the authors.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Importance&#x02014;Pediatric melanoma occurs, albeit rarely. Should patients be treated by today&#x02019;s medical standards, or be subjected to medically unnecessary clinical studies? Observations&#x02014;We identified international, industry-sponsored pediatric melanoma studies triggered by regulatory demands in <uri xlink:href="www.clinicaltrials.gov">www.clinicaltrials.gov</uri> and further pediatric melanoma studies demanded by European Union pediatric investigation plans. We retrieved related regulatory documents from the internet. We analyzed these studies for rationale and medical beneficence on the basis of physiology, pediatric clinical pharmacology and rationale. Regulatory authorities define children by chronological age, not physiologically. Newborns&#x02019; organs are immature but they develop and mature rapidly. Separate proof of efficacy in underage patients is justified formally/regulatorily but lacks medical sense. Children&#x02014;especially post-puberty&#x02014;and adults vis-a-vis medications are physiologically very similar. Two adolescent melanoma studies were terminated in 2016 because of waning recruitment, while five studies in pediatric melanoma and other solid tumors, triggered by European Union pediatric investigation plans, continue recruiting worldwide. Conclusions and Relevance&#x02014;Regulatory-demanded pediatric melanoma studies are medically superfluous. Melanoma patients of all ages should be treated with effective combination treatment. Babies need special attention. Children need dose-finding and pharmacokinetic studies but adolescents metabolize and respond to drugs similarly to adults. Institutional Review Boards/ethics committees should suspend ongoing questionable pediatric melanoma studies and reject newly submitted questionable studies.</p></abstract><kwd-group><kwd>pediatric drug development</kwd><kwd>Pediatric Investigation Plan (PIP)</kwd><kwd>pediatric pharmaceutical legislation</kwd><kwd>EU pediatric regulation</kwd><kwd>pediatric clinical pharmacology</kwd><kwd>developmental pharmacology</kwd><kwd>pediatric laws</kwd><kwd>pediatric clinical studies</kwd></kwd-group></article-meta></front><body><sec id="sec1-children-05-00043"><title>1. Introduction</title><p>Metastatic malignant melanoma, once incurable, can today be treated, even in some cases with durable responses [<xref rid="B1-children-05-00043" ref-type="bibr">1</xref>]. Pediatric melanoma has three major challenges: (1) differentiation between conventional adult-type and other melanoma types [<xref rid="B2-children-05-00043" ref-type="bibr">2</xref>]; (2) differentiation between melanoma simulants that are seen more often in children than in adults (spitz nevi) [<xref rid="B2-children-05-00043" ref-type="bibr">2</xref>]; and (3) treating patients appropriately despite their age [<xref rid="B3-children-05-00043" ref-type="bibr">3</xref>]. The Food and Drug Administration (FDA) and the European Medicines Agency (EMA) promote and require pediatric studies [<xref rid="B4-children-05-00043" ref-type="bibr">4</xref>,<xref rid="B5-children-05-00043" ref-type="bibr">5</xref>,<xref rid="B6-children-05-00043" ref-type="bibr">6</xref>]. In melanoma, such studies appear to recruit predominantly patients with adult-type conventional melanoma [<xref rid="B7-children-05-00043" ref-type="bibr">7</xref>]. A new definition of underage patients in the context of pharmaceutical treatment should be considered, together with a thorough revision of drug approval in the various pediatric age groups.</p></sec><sec id="sec2-children-05-00043"><title>2. Methods</title><p>We identified terminated and ongoing international, industry-sponsored pediatric melanoma studies in <uri xlink:href="www.clinicaltrials.gov">www.clinicaltrials.gov</uri>, excluding studies that recruit(ed) both adolescents and adults to focus on truly pediatric studies. However, we included studies that recruited children, adolescents and young adults up to 30 years of age. We retrieved related EMA/FDA documents from the internet. We identified further pediatric melanoma studies demanded by the EMA in pediatric investigation plans (PIPs). We analyzed the regulatory rationale and medical beneficence of terminated, ongoing and demanded studies on the basis of physiology, pediatric clinical pharmacology and reason. PIP decisions and <uri xlink:href="www.clinicaltrials.gov-listed">www.clinicaltrials.gov-listed</uri> studies can be internet-retrieved by their respective number.</p><sec><title>Background</title><p>Pediatric melanoma is rare but is captured in registries [<xref rid="B8-children-05-00043" ref-type="bibr">8</xref>,<xref rid="B9-children-05-00043" ref-type="bibr">9</xref>,<xref rid="B10-children-05-00043" ref-type="bibr">10</xref>] and is eagerly discussed [<xref rid="B2-children-05-00043" ref-type="bibr">2</xref>,<xref rid="B3-children-05-00043" ref-type="bibr">3</xref>,<xref rid="B11-children-05-00043" ref-type="bibr">11</xref>,<xref rid="B12-children-05-00043" ref-type="bibr">12</xref>,<xref rid="B13-children-05-00043" ref-type="bibr">13</xref>,<xref rid="B14-children-05-00043" ref-type="bibr">14</xref>,<xref rid="B15-children-05-00043" ref-type="bibr">15</xref>,<xref rid="B16-children-05-00043" ref-type="bibr">16</xref>,<xref rid="B17-children-05-00043" ref-type="bibr">17</xref>]. The literature describes it in patients from &#x0003c;10 to &#x02264;21 years of age [<xref rid="B3-children-05-00043" ref-type="bibr">3</xref>]. Should adolescents be therapeutically considered children? The American Academy of Pediatrics (AAP) defines children in the context of healthcare as &#x02264;21 years but accepts pediatric healthcare for older patients with special needs [<xref rid="B18-children-05-00043" ref-type="bibr">18</xref>]. Although these age ranges are appropriate for hands-on pediatric clinical care, they should not be used to limit access to pharmacological treatment.</p><p>The claim that children are discriminated against evolved after US law, in 1962, established clinical trials as the basis for regulatory drug approval, a principle now recognized worldwide [<xref rid="B19-children-05-00043" ref-type="bibr">19</xref>]. Also, jurisdiction over prescription drug advertising was transferred to the FDA [<xref rid="B20-children-05-00043" ref-type="bibr">20</xref>]. In the 1950s, drug toxicities in newborns had been reported [<xref rid="B21-children-05-00043" ref-type="bibr">21</xref>,<xref rid="B22-children-05-00043" ref-type="bibr">22</xref>]. From 1962 onwards, drug developers included pediatric warnings on drug labels to avoid potential lawsuits. As a result, these drugs could not be advertised for children. Shirkey claimed this denied children the use of drugs and characterized children as &#x0201c;therapeutic orphans&#x0201d; [<xref rid="B23-children-05-00043" ref-type="bibr">23</xref>]. The AAP claimed that drug prescription for children without explicit FDA certification was experimental [<xref rid="B24-children-05-00043" ref-type="bibr">24</xref>] and that children needed separate pharmacological evaluation of new drugs for all age groups [<xref rid="B25-children-05-00043" ref-type="bibr">25</xref>]. The AAP guideline of 1995 [<xref rid="B25-children-05-00043" ref-type="bibr">25</xref>] explicitly referenced the toxicities reported in the 1950s [<xref rid="B21-children-05-00043" ref-type="bibr">21</xref>,<xref rid="B22-children-05-00043" ref-type="bibr">22</xref>]. FDA and AAP lobbying resulted in a 1997 law that rewarded pediatric studies with voluntary &#x0201c;pediatric exclusivity&#x0201d; of an additional six months&#x02019; protection against generic competition [<xref rid="B4-children-05-00043" ref-type="bibr">4</xref>]. When a company submits a proposal and the FDA agrees, it issues a &#x0201c;Written Request&#x0201d; (WR). After study report submission and FDA scrutiny, pediatric exclusivity is granted [<xref rid="B4-children-05-00043" ref-type="bibr">4</xref>]. A second law authorized the FDA to mandate pediatric studies without reward [<xref rid="B4-children-05-00043" ref-type="bibr">4</xref>]. Both laws are now permanent [<xref rid="B26-children-05-00043" ref-type="bibr">26</xref>].</p><p>This inspired the European Union (EU) to establish its own pediatric regulation, in effect since 2007 [<xref rid="B4-children-05-00043" ref-type="bibr">4</xref>,<xref rid="B27-children-05-00043" ref-type="bibr">27</xref>]. Without a pediatric investigation plan (PIP), new drugs cannot get adult EU-approval, unless the targeted disease is PIP-exempted [<xref rid="B4-children-05-00043" ref-type="bibr">4</xref>,<xref rid="B5-children-05-00043" ref-type="bibr">5</xref>,<xref rid="B6-children-05-00043" ref-type="bibr">6</xref>]. PIPs must address juvenile animal studies, formulations (e.g., tablets vs. syrup), pediatric studies and more. The EMA has until now issued &#x0003e;1000 PIPs [<xref rid="B28-children-05-00043" ref-type="bibr">28</xref>].</p><p>The reported toxicities had been in premature newborns [<xref rid="B21-children-05-00043" ref-type="bibr">21</xref>,<xref rid="B22-children-05-00043" ref-type="bibr">22</xref>]. Also, further toxicities reported later under the sensational sub-headline &#x0201c;CONTINUED PEDIATRIC THERAPEUTIC DISASTERS&#x0201d; listed until the 1980s only toxicities in preterm newborns and newborns [<xref rid="B29-children-05-00043" ref-type="bibr">29</xref>]. The AAP warnings were, in our opinion, inappropriately extended to all children by &#x0201c;extrapolating&#x0201d; toxicities from physiologically immature newborns to all children. Pediatric laws responded to the AAP&#x02019;s &#x0201c;moral imperative to formally study drugs in children so that they can enjoy equal access to existing as well as new therapeutic agents&#x0201d; [<xref rid="B25-children-05-00043" ref-type="bibr">25</xref>]. Children were defined not based upon physiology but administratively: FDA &#x0003c; 16 [<xref rid="B30-children-05-00043" ref-type="bibr">30</xref>], EU &#x0003c; 18 years [<xref rid="B4-children-05-00043" ref-type="bibr">4</xref>,<xref rid="B6-children-05-00043" ref-type="bibr">6</xref>,<xref rid="B27-children-05-00043" ref-type="bibr">27</xref>].</p></sec></sec><sec id="sec3-children-05-00043"><title>3. Results</title><p>In 2008, the EMA withdrew adolescent melanoma from the list of PIP-exempted diseases [<xref rid="B5-children-05-00043" ref-type="bibr">5</xref>]. Thirteen melanoma PIPs were issued (<xref ref-type="table" rid="children-05-00043-t001">Table 1</xref>). Twelve PIPs demand systemic monotherapy studies in melanoma or solid tumors including melanoma [<xref rid="B5-children-05-00043" ref-type="bibr">5</xref>], this includes the original ipilimumab melanoma PIP [<xref rid="B31-children-05-00043" ref-type="bibr">31</xref>]. The talimogene PIP demands local injection into melanoma and other non-central nervous system (CNS) malignant solid tumors. Two PIP decisions that originally demanded pediatric studies [<xref rid="B32-children-05-00043" ref-type="bibr">32</xref>,<xref rid="B33-children-05-00043" ref-type="bibr">33</xref>] were later changed into waivers (no pediatric studies demanded).</p><p>Melanoma PIPs require variably PK data in patients aged from 6 months to 17 years, 1&#x02013;17, 12&#x02013;17, &#x02264;24 and &#x02264;30 years; for ipilimumab, nivolumab, paclitaxel, pembrolizumab and trametinib they demand randomized comparisons [<xref rid="B5-children-05-00043" ref-type="bibr">5</xref>]. Talimogene is an oncolytic for direct injection into unresectable melanoma tissue [<xref rid="B34-children-05-00043" ref-type="bibr">34</xref>]. The talimogene PIP demands two studies on injection into melanoma tissue or other advanced non-CNS tumors in &#x0201c;pediatric&#x0201d; patients aged 2&#x02013;17 years.</p><p>In 2008, the US National Cancer Institute (NCI) initiated the first pediatric ipilimumab study [<xref rid="B35-children-05-00043" ref-type="bibr">35</xref>]. In 2011, the FDA approved ipilimumab for melanoma [<xref rid="B36-children-05-00043" ref-type="bibr">36</xref>] and the EMA issued an ipilimumab melanoma PIP [<xref rid="B31-children-05-00043" ref-type="bibr">31</xref>]. In 2014, the FDA issued an ipilimumab WR (see <xref ref-type="table" rid="children-05-00043-t002">Table 2</xref>) [<xref rid="B37-children-05-00043" ref-type="bibr">37</xref>]. The developer negotiated with both the EMA and the FDA and provided ipilimumab for the first pediatric NCI study [<xref rid="B35-children-05-00043" ref-type="bibr">35</xref>]. EMA and FDA incorporated the NCI study into their pediatric demands (EMA)/written request (FDA). The NCI study was completed with 33 patients&#x02014;including 12 melanoma patients&#x02014;and was published [<xref rid="B38-children-05-00043" ref-type="bibr">38</xref>]. The PIP/WR ipilimumab clinical study #2 was initiated, listed on <uri xlink:href="www.clinicaltrials.gov">www.clinicaltrials.gov</uri> [<xref rid="B39-children-05-00043" ref-type="bibr">39</xref>] and eventually reported [<xref rid="B40-children-05-00043" ref-type="bibr">40</xref>].</p><p>Two industry-sponsored international melanoma studies in adolescents were terminated in 2016 because recruitment had waned, predominantly due to now available combination treatment (<xref ref-type="table" rid="children-05-00043-t003">Table 3</xref>) [<xref rid="B41-children-05-00043" ref-type="bibr">41</xref>]. The ipilimumab study had been both WR/PIP-requested [<xref rid="B5-children-05-00043" ref-type="bibr">5</xref>], the vemurafenib study PIP-demanded (<xref ref-type="table" rid="children-05-00043-t003">Table 3</xref>) [<xref rid="B42-children-05-00043" ref-type="bibr">42</xref>]. After the vemurafenib study was terminated, the EMA changed the vemurafenib PIP decision (<xref ref-type="table" rid="children-05-00043-t003">Table 3</xref>) into a waiver, although the original decision had already triggered a clinical study [<xref rid="B42-children-05-00043" ref-type="bibr">42</xref>].</p><p>Five industry-sponsored, PIP-demanded studies in children, adolescents and young adults with melanoma and other tumors are ongoing (<xref ref-type="table" rid="children-05-00043-t004">Table 4</xref>). For studies&#x02019; centers, see <xref ref-type="table" rid="children-05-00043-t005">Table 5</xref>.</p></sec><sec id="sec4-children-05-00043"><title>4. Discussion</title><p>Industry-sponsored pediatric melanoma studies are driven by the FDA/EMA in the spirit of the &#x0201c;therapeutic orphans&#x0201d; concept. These studies are regulatorily justified on the assumption of two distinct populations, adult versus pediatric, each requiring separate studies. Both US and EU laws claim concern for child health but closer inspection of key documents shows a regulatory rationale. For the FDA, a good example is the shift of wording from the FDA&#x02019;s first pediatric report to congress in 2001 to the second one in 2016. In 2001, it described expected clinical outcomes: &#x0201c;quicker recoveries from childhood illnesses, with fewer attendant hospital stays, physician visits and parental work days lost&#x0201d; [<xref rid="B43-children-05-00043" ref-type="bibr">43</xref>]. In 2016, it reported &#x0201c;significant progress in terms of the number, timeliness and successful completion of studies of drugs in pediatric populations&#x0201d; [<xref rid="B44-children-05-00043" ref-type="bibr">44</xref>]. This a shift away from clinical concerns towards a regulatory justification of pediatric studies. Also, the EMA wording suggests clinical concern, for example, their brochure entitled &#x0201c;Better Medicines for Children&#x0201d; [<xref rid="B45-children-05-00043" ref-type="bibr">45</xref>]. However, the focus in this brochure is the authorization of drugs, not clinical care. The EMA 10-year report on EU pediatric regulation [<xref rid="B46-children-05-00043" ref-type="bibr">46</xref>] in comparison to its recent publication by EMA employees [<xref rid="B47-children-05-00043" ref-type="bibr">47</xref>] demonstrates their true motivation.</p><p>We find it questionable that the EMA required pediatric clinical studies in the first vemurafenib melanoma PIP [<xref rid="B33-children-05-00043" ref-type="bibr">33</xref>] but thereafter changed the PIP decision into a full waiver (no pediatric studies required, <xref ref-type="table" rid="children-05-00043-t003">Table 3</xref>), without a public explanation for why it had first required the developing company to initiate a study [<xref rid="B42-children-05-00043" ref-type="bibr">42</xref>] and then waived this decision. Additionally, there are several clinical studies listed in <uri xlink:href="www.clinicaltrials.gov">www.clinicaltrials.gov</uri> for talimogene laherparepvec for various cancer types. If one of them should show statistically significant superiority, Amgen would ask for approval for a new indication. However, there is no medical merit in requiring Amgen to recruit 18 young patients to participate in an international clinical study with 17 centers (see <xref ref-type="table" rid="children-05-00043-t004">Table 4</xref> and <xref ref-type="table" rid="children-05-00043-t005">Table 5</xref>) for various non-central nervous system tumor types, including melanoma. All these patients have in common is that they are young (<xref ref-type="table" rid="children-05-00043-t004">Table 4</xref>). These 18 patients are being studied because of a regulatory authority enforcing pediatric studies. Meanwhile these patients are not being advantaged of the newer combination therapies that are available.</p><p>Children and adolescents with adult-type conventional melanomas [<xref rid="B2-children-05-00043" ref-type="bibr">2</xref>] should be treated with proven medications that are dose-adjusted for their weight and physiology. In preterm newborns, newborns and babies, absorption, distribution and excretion (ADME) are quite different. After roughly the first year of life, ADME becomes comparable to adults [<xref rid="B48-children-05-00043" ref-type="bibr">48</xref>]. Children need PK- and dose-finding studies, not separate proof of efficacy. Adolescents have mature bodies as far as pharmaceutical treatment is concerned. Patients of all ages deserve treatment with effective anti-melanoma combinations. This holds true even for the very rare cases of melanoma in babies and newborns, provided conventional melanoma is sufficiently differentiated from other melanoma types [<xref rid="B2-children-05-00043" ref-type="bibr">2</xref>]. Institutional Review Boards (IRBs)/ethics committees (ECs) should not have approved the terminated studies (<xref ref-type="table" rid="children-05-00043-t003">Table 3</xref>). The &#x0201c;pediatric&#x0201d; phase 1 ipilimumab study in children, adolescents and young adults [<xref rid="B35-children-05-00043" ref-type="bibr">35</xref>,<xref rid="B38-children-05-00043" ref-type="bibr">38</xref>] continued even after ipilimumab approval. After ipilimumab approval in 2011 this was no longer experimental, no longer a phase 1 study and had not been a pediatric study from the beginning.</p><p>Within pediatric academic clinical oncology, an international industry has evolved that is dedicated to FDA/EMA-promoted &#x0201c;pediatric&#x0201d; studies, as reflected in the number of study centers and planned patients in <xref ref-type="table" rid="children-05-00043-t003">Table 3</xref>, <xref ref-type="table" rid="children-05-00043-t004">Table 4</xref> and <xref ref-type="table" rid="children-05-00043-t005">Table 5</xref>. Not all clinical researchers involved in international pediatric melanoma studies are aware of the regulatory background. Participation in international studies offers prestige, networking, investigators&#x02019; meetings, opportunities to publish and more. Certainly, the flow of funds is welcome. These funds are channeled by regulatory decisions. The regulatory authorities have been given much credit in promoting pediatric research but the studies we discuss here are to a large degree not pediatric studies and are without clinical beneficence. The conflicts of interest of regulatory authorities and pediatric researchers have so far been barely addressed in the scientific literature. It is time for medicine and academia to address this blind spot.</p></sec><sec id="sec5-children-05-00043"><title>5. Conclusions</title><p>IRBs/ECs should immediately suspend, worldwide, questionable monotherapy melanoma studies and reject newly submitted unnecessary pediatric studies. Melanoma patients from suspended studies should be offered combination treatment; other patients should be offered appropriate therapy, not monotherapy based on questionable regulatory requirements for pediatric studies. IRBs/ECs should uphold the Belmont report&#x02019;s principle of beneficence [<xref rid="B49-children-05-00043" ref-type="bibr">49</xref>].</p></sec></body><back><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>Klaus Rose has worked 20 years in pharmaceutical industry in clinical development and medical affairs. Independent since 2011, he consults on pediatric drug development, teaches, organizes conferences, edits books, and publishes. He receives annual royalties for a co-edited book on pediatric formulations. He still owns shares of his former employers Roche/Genentech and Novartis. His clients are pharmaceutical companies and academic institutions. He is also the father of a daughter with a rare syndrome and is biased against empty governmental promises. Jane Grant-Kels declares no competing interests.</p></notes><ref-list><title>References</title><ref id="B1-children-05-00043"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lejeune</surname><given-names>F.J.</given-names></name></person-group><article-title>The conquest of melanoma by immunotherapy</article-title><source>Melanoma Res.</source><year>2015</year><volume>25</volume><fpage>373</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1097/CMR.0000000000000178</pub-id><pub-id pub-id-type="pmid">26173006</pub-id></element-citation></ref><ref id="B2-children-05-00043"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pappo</surname><given-names>A.S.</given-names></name></person-group><article-title>Pediatric Melanoma: The Whole (Genome) Story</article-title><source>Am. Soc. Clin. Oncol. Educ. Book</source><year>2014</year><fpage>e432</fpage><lpage>e435</lpage><pub-id pub-id-type="doi">10.14694/EdBook_AM.2014.34.e432</pub-id><pub-id pub-id-type="pmid">24857134</pub-id></element-citation></ref><ref id="B3-children-05-00043"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wood</surname><given-names>B.A.</given-names></name></person-group><article-title>Paediatric Melanoma</article-title><source>Pathology</source><year>2016</year><volume>48</volume><fpage>155</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1016/j.pathol.2015.12.001</pub-id><pub-id pub-id-type="pmid">27020388</pub-id></element-citation></ref><ref id="B4-children-05-00043"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirschfeld</surname><given-names>S.</given-names></name><name><surname>Saint-Raymond</surname><given-names>A.</given-names></name></person-group><article-title>Pediatric Regulatory Initiatives</article-title><source>Handb. Exp. Pharmacol.</source><year>2011</year><volume>205</volume><fpage>245</fpage><lpage>268</lpage><pub-id pub-id-type="pmid">21882115</pub-id></element-citation></ref><ref id="B5-children-05-00043"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rose</surname><given-names>K.</given-names></name><name><surname>Walson</surname><given-names>P.D.</given-names></name></person-group><article-title>Do the European Medicines Agency (EMA) decisions hurt pediatric melanoma patients?</article-title><source>Clin. Ther.</source><year>2017</year><volume>39</volume><fpage>253</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1016/j.clinthera.2017.01.009</pub-id><pub-id pub-id-type="pmid">28159363</pub-id></element-citation></ref><ref id="B6-children-05-00043"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rose</surname><given-names>K.</given-names></name><name><surname>Walson</surname><given-names>P.D.</given-names></name></person-group><article-title>Do Pediatric Investigation Plans (PIPs) advance pediatric healthcare?</article-title><source>Pediatr. Drugs</source><year>2017</year><volume>19</volume><fpage>515</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1007/s40272-017-0260-2</pub-id><pub-id pub-id-type="pmid">28889403</pub-id></element-citation></ref><ref id="B7-children-05-00043"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rose</surname><given-names>K.</given-names></name><name><surname>Grant-Kels</surname><given-names>J.</given-names></name></person-group><article-title>Most adolescents&#x02019; melanomas are conventional malignant adult-type melanomas</article-title><source>Eur. J. Cancer</source><year>2018</year><comment>in press</comment><pub-id pub-id-type="doi">10.1016/j.ejca.2018.01.080</pub-id><pub-id pub-id-type="pmid">29475773</pub-id></element-citation></ref><ref id="B8-children-05-00043"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>J.R.</given-names></name><name><surname>Harris</surname><given-names>J.K.</given-names></name><name><surname>Rodriguez-Galindo</surname><given-names>C.</given-names></name><name><surname>Johnson</surname><given-names>K.J.</given-names></name></person-group><article-title>Incidence of childhood and adolescent melanoma in the United States: 1973&#x02013;2009</article-title><source>Paediatrics</source><year>2013</year><volume>131</volume><fpage>846</fpage><lpage>857</lpage><pub-id pub-id-type="doi">10.1542/peds.2012-2520</pub-id><pub-id pub-id-type="pmid">23589817</pub-id></element-citation></ref><ref id="B9-children-05-00043"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brecht</surname><given-names>I.B.</given-names></name><name><surname>Garbe</surname><given-names>C.</given-names></name><name><surname>Gefeller</surname><given-names>O.</given-names></name><name><surname>Pfahlberg</surname><given-names>A.</given-names></name><name><surname>Bauer</surname><given-names>J.</given-names></name><name><surname>Eigentler</surname><given-names>T.K.</given-names></name><name><surname>Offenmueller</surname><given-names>S.</given-names></name><name><surname>Schneider</surname><given-names>D.T.</given-names></name><name><surname>Leiter</surname><given-names>U.</given-names></name></person-group><article-title>443 paediatric cases of malignant melanoma registered with the German Central Malignant Melanoma Registry between 1983 and 2011</article-title><source>Eur. J. Cancer</source><year>2015</year><volume>51</volume><fpage>861</fpage><lpage>868</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2015.02.014</pub-id><pub-id pub-id-type="pmid">25794606</pub-id></element-citation></ref><ref id="B10-children-05-00043"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eggen</surname><given-names>C.A.M.</given-names></name><name><surname>Durgaram</surname><given-names>V.V.L.</given-names></name><name><surname>van Doorn</surname><given-names>R.</given-names></name><name><surname>Mooi</surname><given-names>W.J.</given-names></name><name><surname>Pardo</surname><given-names>L.M.</given-names></name><name><surname>Pasmans</surname><given-names>S.G.M.A.</given-names></name><name><surname>Hollestein</surname><given-names>L.M.</given-names></name></person-group><article-title>Incidence and relative survival of melanoma in children and adolescents in the Netherlands, 1989&#x02013;2013</article-title><source>J. Eur. Acad. Dermatol. Venereol.</source><year>2017</year><pub-id pub-id-type="doi">10.1111/jdv.14665</pub-id><pub-id pub-id-type="pmid">29080310</pub-id></element-citation></ref><ref id="B11-children-05-00043"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abboud</surname><given-names>J.</given-names></name><name><surname>Stein</surname><given-names>M.</given-names></name><name><surname>Ramien</surname><given-names>M.</given-names></name><name><surname>Malic</surname><given-names>C.</given-names></name></person-group><article-title>The diagnosis and management of the Spitz nevus in the pediatric population: A systematic review and meta-analysis protocol</article-title><source>Syst. Rev.</source><year>2017</year><volume>6</volume><fpage>81</fpage><pub-id pub-id-type="doi">10.1186/s13643-017-0477-8</pub-id><pub-id pub-id-type="pmid">28407793</pub-id></element-citation></ref><ref id="B12-children-05-00043"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LaChance</surname><given-names>A.</given-names></name><name><surname>Shahriari</surname><given-names>M.</given-names></name><name><surname>Kerr</surname><given-names>P.E.</given-names></name><name><surname>Grant-Kels</surname><given-names>J.M.</given-names></name></person-group><article-title>Melanoma: Kids are not just little people</article-title><source>Clin. Dermatol.</source><year>2016</year><volume>34</volume><fpage>742</fpage><lpage>748</lpage><pub-id pub-id-type="doi">10.1016/j.clindermatol.2016.07.009</pub-id><pub-id pub-id-type="pmid">27968934</pub-id></element-citation></ref><ref id="B13-children-05-00043"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Offenmueller</surname><given-names>S.</given-names></name><name><surname>Leiter</surname><given-names>U.</given-names></name><name><surname>Bernbeck</surname><given-names>B.</given-names></name><name><surname>Garbe</surname><given-names>C.</given-names></name><name><surname>Eigentler</surname><given-names>T.</given-names></name><name><surname>Borkhardt</surname><given-names>A.</given-names></name><name><surname>Classen</surname><given-names>C.F.</given-names></name><name><surname>Corbacioglu</surname><given-names>S.</given-names></name><name><surname>Dirksen</surname><given-names>U.</given-names></name><name><surname>Ebetsberger-Dachs</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Clinical characteristics and outcome of 60 pediatric patients with malignant melanoma registered with the German Pediatric Rare Tumor Registry (STEP)</article-title><source>Klin. Padiatr.</source><year>2017</year><volume>229</volume><fpage>322</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1055/s-0043-118662</pub-id><pub-id pub-id-type="pmid">29017184</pub-id></element-citation></ref><ref id="B14-children-05-00043"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carrera</surname><given-names>C.</given-names></name><name><surname>Scope</surname><given-names>A.</given-names></name><name><surname>Dusza</surname><given-names>S.W.</given-names></name><name><surname>Argenziano</surname><given-names>G.</given-names></name><name><surname>Nazzaro</surname><given-names>G.</given-names></name><name><surname>Phan</surname><given-names>A.</given-names></name><name><surname>Tromme</surname><given-names>I.</given-names></name><name><surname>Rubegni</surname><given-names>P.</given-names></name><name><surname>Malvehy</surname><given-names>J.</given-names></name><name><surname>Puig</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Clinical and dermoscopic characterization of pediatric and adolescent melanomas: Multicenter study of 52 cases</article-title><source>J. Am. Acad. Dermatol.</source><year>2018</year><volume>78</volume><fpage>278</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2017.09.065</pub-id><pub-id pub-id-type="pmid">29024734</pub-id></element-citation></ref><ref id="B15-children-05-00043"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tracy</surname><given-names>E.T.</given-names></name><name><surname>Aldrink</surname><given-names>J.H.</given-names></name></person-group><article-title>Pediatric melanoma</article-title><source>Semin. Pediatr. Surg.</source><year>2016</year><volume>25</volume><fpage>290</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1053/j.sempedsurg.2016.09.010</pub-id><pub-id pub-id-type="pmid">27955732</pub-id></element-citation></ref><ref id="B16-children-05-00043"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stefanaki</surname><given-names>C.</given-names></name><name><surname>Chardalias</surname><given-names>L.</given-names></name><name><surname>Soura</surname><given-names>E.</given-names></name><name><surname>Katsarou</surname><given-names>A.</given-names></name><name><surname>Stratigos</surname><given-names>A.</given-names></name></person-group><article-title>Pediatric Melanoma</article-title><source>J. Eur. Acad. Dermatol. Venereol.</source><year>2017</year><volume>31</volume><fpage>1604</fpage><lpage>1615</lpage><pub-id pub-id-type="doi">10.1111/jdv.14299</pub-id><pub-id pub-id-type="pmid">28449284</pub-id></element-citation></ref><ref id="B17-children-05-00043"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Nagahawatte</surname><given-names>P.</given-names></name><name><surname>Easton</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Ding</surname><given-names>L.</given-names></name><name><surname>Wyczalkowski</surname><given-names>M.A.</given-names></name><name><surname>Valentine</surname><given-names>M.</given-names></name><name><surname>Navid</surname><given-names>F.</given-names></name><etal/></person-group><article-title>The Genomic Landscape of Childhood and Adolescent Melanoma</article-title><source>J. Investig. Dermatol.</source><year>2015</year><volume>135</volume><fpage>816</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1038/jid.2014.425</pub-id><pub-id pub-id-type="pmid">25268584</pub-id></element-citation></ref><ref id="B18-children-05-00043"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hardin</surname><given-names>A.P.</given-names></name><name><surname>Hackell</surname><given-names>J.M.</given-names></name><collab>Committee on Practice and Ambulatory Medicine</collab></person-group><article-title>Age Limit of Pediatrics</article-title><source>Pediatrics</source><year>2017</year><volume>140</volume><fpage>e20172151</fpage><pub-id pub-id-type="doi">10.1542/peds.2017-2151</pub-id><pub-id pub-id-type="pmid">28827380</pub-id></element-citation></ref><ref id="B19-children-05-00043"><label>19.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>R&#x000e4;go</surname><given-names>L.</given-names></name><name><surname>Santo</surname><given-names>B.</given-names></name></person-group><article-title>Drug Regulation: History, Present and Future</article-title><source>Drug Benefits and Risks: International Textbook of Clinical Pharmacology</source><edition>2nd ed.</edition><person-group person-group-type="editor"><name><surname>van Boxtel</surname><given-names>C.J.</given-names></name><name><surname>Santo</surname><given-names>B.</given-names></name><name><surname>Edwards</surname><given-names>I.R.</given-names></name></person-group><publisher-name>IOS Press &#x00026; Uppsala Monitoring Centre</publisher-name><publisher-loc>Uppsala, Sweden</publisher-loc><year>2008</year><comment>Chapter 6</comment><fpage>65</fpage><lpage>77</lpage></element-citation></ref><ref id="B20-children-05-00043"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donohue</surname><given-names>J.</given-names></name></person-group><article-title>A History of Drug Advertising: The Evolving Roles of Consumers and Consumer Protection</article-title><source>Milbank Q.</source><year>2006</year><volume>84</volume><fpage>659</fpage><lpage>699</lpage><pub-id pub-id-type="doi">10.1111/j.1468-0009.2006.00464.x</pub-id><pub-id pub-id-type="pmid">17096638</pub-id></element-citation></ref><ref id="B21-children-05-00043"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burns</surname><given-names>L.E.</given-names></name><name><surname>Hodgman</surname><given-names>J.E.</given-names></name><name><surname>Cass</surname><given-names>A.B.</given-names></name></person-group><article-title>Fatal circulatory collapse in premature infants receiving chloramphenicol</article-title><source>N. Engl. J. Med.</source><year>1959</year><volume>261</volume><fpage>1318</fpage><lpage>1321</lpage><pub-id pub-id-type="doi">10.1056/NEJM195912242612604</pub-id><pub-id pub-id-type="pmid">13806261</pub-id></element-citation></ref><ref id="B22-children-05-00043"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silverman</surname><given-names>W.A.</given-names></name><name><surname>Andersen</surname><given-names>D.H.</given-names></name><name><surname>Blanc</surname><given-names>W.A.</given-names></name><name><surname>Crozier</surname><given-names>D.N.</given-names></name></person-group><article-title>A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic antibacterial regimens</article-title><source>Pediatrics</source><year>1956</year><volume>18</volume><fpage>614</fpage><lpage>625</lpage><pub-id pub-id-type="pmid">13370229</pub-id></element-citation></ref><ref id="B23-children-05-00043"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shirkey</surname><given-names>H.</given-names></name></person-group><article-title>Therapeutic Orphans</article-title><source>J. Pediatr.</source><year>1968</year><volume>72</volume><fpage>119</fpage><lpage>120</lpage><comment>reprinted in <italic>Pediatrics</italic><bold>1999</bold>, <italic>104</italic>, 583&#x02013;584</comment><pub-id pub-id-type="doi">10.1016/S0022-3476(68)80414-7</pub-id><pub-id pub-id-type="pmid">5634934</pub-id></element-citation></ref><ref id="B24-children-05-00043"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>American Academy of Pediatrics (AAP)</collab></person-group><article-title>Committee on Drugs. Guidelines for the Ethical Conduct of Studies to Evaluate Drugs in Pediatric Populations</article-title><source>Pediatrics</source><year>1977</year><volume>60</volume><fpage>91</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">876741</pub-id></element-citation></ref><ref id="B25-children-05-00043"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>American Academy of Pediatrics</collab></person-group><article-title>Guidelines for the Ethical Conduct of Studies to Evaluate Drugs in Pediatric Populations, Committee on Drugs</article-title><source>Pediatrics</source><year>1995</year><volume>95</volume><fpage>286</fpage><lpage>294</lpage><pub-id pub-id-type="pmid">7838651</pub-id></element-citation></ref><ref id="B26-children-05-00043"><label>26.</label><element-citation publication-type="gov"><article-title>Food and Drug Administration Safety and Innovation Act (FDASIA)</article-title><year>2012</year><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.congress.gov/112/plaws/publ144/PLAW-112publ144.pdf">https://www.congress.gov/112/plaws/publ144/PLAW-112publ144.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2018-03-16">(accessed on 16 March 2018)</date-in-citation></element-citation></ref><ref id="B27-children-05-00043"><label>27.</label><element-citation publication-type="web"><article-title>Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on Medicinal Products for Paediatric Use and Amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://ec.europa.eu/health/files/eudralex/vol-1/reg_2006_1901/reg_2006_1901_en.pdf">http://ec.europa.eu/health/files/eudralex/vol-1/reg_2006_1901/reg_2006_1901_en.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2018-03-16">(accessed on 16 March 2018)</date-in-citation></element-citation></ref><ref id="B28-children-05-00043"><label>28.</label><element-citation publication-type="web"><article-title>EU Commission Report 2017: State of Paediatric Medicines in the EU&#x02014;10 years of the EU Paediatric Regulation</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://ec.europa.eu/health/sites/health/files/files/paediatrics/docs/2017_childrensmedicines_report_en.pdf">https://ec.europa.eu/health/sites/health/files/files/paediatrics/docs/2017_childrensmedicines_report_en.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2018-03-16">(accessed on 16 March 2018)</date-in-citation></element-citation></ref><ref id="B29-children-05-00043"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christensen</surname><given-names>M.L.</given-names></name><name><surname>Helms</surname><given-names>R.A.</given-names></name><name><surname>Chesney</surname><given-names>R.W.</given-names></name></person-group><article-title>Is pediatric labeling really necessary?</article-title><source>Pediatrics</source><year>1999</year><volume>104</volume><issue>Suppl. 3</issue><fpage>593</fpage><lpage>597</lpage><pub-id pub-id-type="pmid">10469796</pub-id></element-citation></ref><ref id="B30-children-05-00043"><label>30.</label><element-citation publication-type="gov"><person-group person-group-type="author"><name><surname>Hirschfeld</surname><given-names>S.</given-names></name></person-group><article-title>History of Pediatric Labeling</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.google.ch/url?sa=t&#x00026;rct=j&#x00026;q=&#x00026;esrc=s&#x00026;source=web&#x00026;cd=1&#x00026;cad=rja&#x00026;uact=8&#x00026;ved=0ahUKEwjn2YXDr5HYAhUDUBQKHe81DYcQFggzMAA&#x00026;url=https%3A%2F%2Fwww.fda.gov%2Fohrms%2Fdockets%2Fac%2F03%2Fslides%2F3927S1_01_Hirshfeld%2520.ppt&#x00026;usg=AOvVaw2uP6W-YOVM7YYk0cq44bm8">https://www.google.ch/url?sa=t&#x00026;rct=j&#x00026;q=&#x00026;esrc=s&#x00026;source=web&#x00026;cd=1&#x00026;cad=rja&#x00026;uact=8&#x00026;ved=0ahUKEwjn2YXDr5HYAhUDUBQKHe81DYcQFggzMAA&#x00026;url=https%3A%2F%2Fwww.fda.gov%2Fohrms%2Fdockets%2Fac%2F03%2Fslides%2F3927S1_01_Hirshfeld%2520.ppt&#x00026;usg=AOvVaw2uP6W-YOVM7YYk0cq44bm8</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2018-03-16">(accessed on 16 March 2018)</date-in-citation></element-citation></ref><ref id="B31-children-05-00043"><label>31.</label><element-citation publication-type="web"><article-title>EMEA-000117-PIP02-10</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu/docs/en_GB/document_library/PIP_decision/WC500108733.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/PIP_decision/WC500108733.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2018-03-16">(accessed on 16 March 2018)</date-in-citation></element-citation></ref><ref id="B32-children-05-00043"><label>32.</label><element-citation publication-type="web"><article-title>Original MAGE-A3 Recombinant Protein PIP Decision EMEA-001099-PIP02-11</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu/docs/en_GB/document_library/PIP_decision/WC500131210.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/PIP_decision/WC500131210.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2018-03-16">(accessed on 16 March 2018)</date-in-citation></element-citation></ref><ref id="B33-children-05-00043"><label>33.</label><element-citation publication-type="web"><article-title>Vemurafenib PIP</article-title><year>2011</year><comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu/docs/en_GB/document_library/PIP_decision/WC500106279.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/PIP_decision/WC500106279.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2018-03-16">(accessed on 16 March 2018)</date-in-citation></element-citation></ref><ref id="B34-children-05-00043"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fountzilas</surname><given-names>C.</given-names></name><name><surname>Patel</surname><given-names>S.</given-names></name><name><surname>Mahalingam</surname><given-names>D.</given-names></name></person-group><article-title>Review: Oncolytic virotherapy, updates and future directions</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>102617</fpage><lpage>102639</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.18309</pub-id><pub-id pub-id-type="pmid">29254276</pub-id></element-citation></ref><ref id="B35-children-05-00043"><label>35.</label><element-citation publication-type="gov"><article-title>Phase, I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents with Treatment-Resistant Cancer</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01445379">https://clinicaltrials.gov/ct2/show/NCT01445379</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2018-03-16">(accessed on 16 March 2018)</date-in-citation></element-citation></ref><ref id="B36-children-05-00043"><label>36.</label><element-citation publication-type="gov"><article-title>Ipilimumab Prescribing Information</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125377s073lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125377s073lbl.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2018-03-16">(accessed on 16 March 2018)</date-in-citation></element-citation></ref><ref id="B37-children-05-00043"><label>37.</label><element-citation publication-type="gov"><article-title>Ipilimumab Written Request 2014</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM571258.pdf">https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM571258.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2018-03-16">(accessed on 16 March 2018)</date-in-citation></element-citation></ref><ref id="B38-children-05-00043"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merchant</surname><given-names>M.</given-names></name><name><surname>Wright</surname><given-names>M.</given-names></name><name><surname>Baird</surname><given-names>K.</given-names></name><name><surname>Wexler</surname><given-names>L.</given-names></name><name><surname>Rodriguez-Galindo</surname><given-names>C.</given-names></name><name><surname>Bernstein</surname><given-names>D.</given-names></name><name><surname>Delbrook</surname><given-names>C.</given-names></name><name><surname>Lodish</surname><given-names>M.</given-names></name><name><surname>Bishop</surname><given-names>R.</given-names></name><name><surname>Wolchok</surname><given-names>J.D.</given-names></name><etal/></person-group><article-title>Phase 1 trial of Ipilumamb in Ipilimumab in ped patients with advanced solid tumors</article-title><source>Clin. Cancer Res.</source><year>2016</year><volume>22</volume><fpage>1364</fpage><lpage>1370</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-0491</pub-id><pub-id pub-id-type="pmid">26534966</pub-id></element-citation></ref><ref id="B39-children-05-00043"><label>39.</label><element-citation publication-type="gov"><article-title>Phase 2 Study of Ipilimumab in Children and Adolescents (12 to &#x0003c; 18 Years) with Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01696045">https://clinicaltrials.gov/ct2/show/NCT01696045</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2018-03-16">(accessed on 16 March 2018)</date-in-citation></element-citation></ref><ref id="B40-children-05-00043"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geoerger</surname><given-names>B.</given-names></name><name><surname>Bergeron</surname><given-names>C.</given-names></name><name><surname>Gore</surname><given-names>L.</given-names></name><name><surname>Sender</surname><given-names>L.</given-names></name><name><surname>Dunkel</surname><given-names>I.J.</given-names></name><name><surname>Herzog</surname><given-names>C.</given-names></name><name><surname>Brochez</surname><given-names>L.</given-names></name><name><surname>Cruz</surname><given-names>O.</given-names></name><name><surname>Nysom</surname><given-names>K.</given-names></name><name><surname>Berghorn</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma</article-title><source>Eur. J. Cancer</source><year>2017</year><volume>86</volume><fpage>358</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2017.09.032</pub-id><pub-id pub-id-type="pmid">29100190</pub-id></element-citation></ref><ref id="B41-children-05-00043"><label>41.</label><element-citation publication-type="gov"><article-title>FDA Ipilimumab Clinical Review 125377/Supplement 87</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM572924.pdf">https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM572924.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2018-03-16">(accessed on 16 March 2018)</date-in-citation></element-citation></ref><ref id="B42-children-05-00043"><label>42.</label><element-citation publication-type="gov"><article-title>BRIM-P: A Study of Vemurafenib in Pediatric Patients with Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT01519323">https://www.clinicaltrials.gov/ct2/show/NCT01519323</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2018-03-16">(accessed on 16 March 2018)</date-in-citation></element-citation></ref><ref id="B43-children-05-00043"><label>43.</label><element-citation publication-type="gov"><article-title>The Pediatric Exclusivity Provision; January 2001</article-title><comment>Status Report to Congress</comment><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM049915.pdf">https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM049915.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2018-03-16">(accessed on 16 March 2018)</date-in-citation></element-citation></ref><ref id="B44-children-05-00043"><label>44.</label><element-citation publication-type="book"><article-title>Best Pharmaceuticals for Children Act and Pediatric Research Equity Act</article-title><month>7</month><year>2016</year><comment>Status Report to Congress</comment><publisher-name>Department of Health and Human Services</publisher-name><publisher-name>Food and Drug Administration</publisher-name><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/downloads/ScienceResearch/SpecialTopics/PediatricTherapeuticsResearch/UCM509815.pdf">https://www.fda.gov/downloads/ScienceResearch/SpecialTopics/PediatricTherapeuticsResearch/UCM509815.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2018-03-16">(accessed on 16 March 2018)</date-in-citation></element-citation></ref><ref id="B45-children-05-00043"><label>45.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>European Medicines Agency</collab></person-group><article-title>Better Medicines for Children</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2009/12/WC500026493.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2009/12/WC500026493.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2018-03-16">(accessed on 16 March 2018)</date-in-citation></element-citation></ref><ref id="B46-children-05-00043"><label>46.</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>European Medicines Agency</collab></person-group><article-title>10-Year Report to the European Commission. General Report on the Experience Acquired as a Result of the Application of the Paediatric Regulation</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://ec.europa.eu/health/sites/health/files/files/paediatrics/2016_pc_report_2017/ema_10_year_report_for_consultation.pdf">https://ec.europa.eu/health/sites/health/files/files/paediatrics/2016_pc_report_2017/ema_10_year_report_for_consultation.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2018-03-16">(accessed on 16 March 2018)</date-in-citation></element-citation></ref><ref id="B47-children-05-00043"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomasi</surname><given-names>P.A.</given-names></name><name><surname>Egger</surname><given-names>G.F.</given-names></name><name><surname>Pallidis</surname><given-names>C.</given-names></name><name><surname>Saint-Raymond</surname><given-names>A.</given-names></name></person-group><article-title>Enabling Development of Paediatric Medicines in Europe: 10 Years of the EU Paediatric Regulation</article-title><source>Pediatr. Drugs</source><year>2017</year><volume>19</volume><fpage>501</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1007/s40272-017-0261-1</pub-id><pub-id pub-id-type="pmid">28900869</pub-id></element-citation></ref><ref id="B48-children-05-00043"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kearns</surname><given-names>G.L.</given-names></name><name><surname>Abdel-Rahman</surname><given-names>S.M.</given-names></name><name><surname>Alander</surname><given-names>S.W.</given-names></name><name><surname>Blowey</surname><given-names>D.L.</given-names></name><name><surname>Leeder</surname><given-names>J.S.</given-names></name><name><surname>Kauffman</surname><given-names>R.E.</given-names></name></person-group><article-title>Developmental pharmacology&#x02014;Drug disposition, action and therapy in infants and children</article-title><source>N. Engl. J. Med.</source><year>2003</year><volume>349</volume><fpage>1157</fpage><lpage>1167</lpage><pub-id pub-id-type="doi">10.1056/NEJMra035092</pub-id><pub-id pub-id-type="pmid">13679531</pub-id></element-citation></ref><ref id="B49-children-05-00043"><label>49.</label><element-citation publication-type="gov"><article-title>The Belmont Report. Ethical Principles and Guidelines for the Protection of Human Subjects of Research</article-title><comment>The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research April 18, 1979</comment><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4178b_09_02_Belmont%20Report.pdf">https://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4178b_09_02_Belmont%20Report.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2018-03-16">(accessed on 16 March 2018)</date-in-citation></element-citation></ref></ref-list></back><floats-group><table-wrap id="children-05-00043-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">children-05-00043-t001_Table 1</object-id><label>Table 1</label><caption><p>European Medicines Agency (EMA) melanoma Pediatric Investigation Plans (PIPs).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Compound</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PIP Number</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Binimetinib</td><td align="left" valign="middle" rowspan="1" colspan="1">EMEA-001454-PIP03-15</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Cobimetinib</td><td align="left" valign="middle" rowspan="1" colspan="1">EMEA-001425-PIP01-13-M01</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Dabrafenib</td><td align="left" valign="middle" rowspan="1" colspan="1">EMEA&#x02013;001147-PIP01-11-M03</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Encorafenib</td><td align="left" valign="middle" rowspan="1" colspan="1">EMEA-001588-PIP01-13</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Ipilimumab *</td><td align="left" valign="middle" rowspan="1" colspan="1">EMEA-000117-PIP02-10 [<xref rid="B31-children-05-00043" ref-type="bibr">31</xref>] &#x02022; EMEA-000117-PIP02-10-M07</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MAGE-A3 recombinant protein **</td><td align="left" valign="middle" rowspan="1" colspan="1">EMEA-001099-PIP02-11 [<xref rid="B32-children-05-00043" ref-type="bibr">32</xref>] &#x02022; EMEA-001099-PIP02-11-M01</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Nivolumab</td><td align="left" valign="middle" rowspan="1" colspan="1">EMEA-001407-PIP01-12</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Paclitaxel</td><td align="left" valign="middle" rowspan="1" colspan="1">EMEA-001308-PIP01-12</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Pembrolizumab</td><td align="left" valign="middle" rowspan="1" colspan="1">EMEA-001474-PIP01-13</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Selumetinib</td><td align="left" valign="middle" rowspan="1" colspan="1">EMEA-001585-PIP01-13</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Talimogene laherparapvec</td><td align="left" valign="middle" rowspan="1" colspan="1">EMEA-001251-PIP01-11-M03</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Trametinib </td><td align="left" valign="middle" rowspan="1" colspan="1">EMEA-001177-PIP01-11-M02</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vemurafenib **</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EMEA-000978-PIP01-10 [<xref rid="B33-children-05-00043" ref-type="bibr">33</xref>] &#x02022; EMEA-000978-PIP01-10-M01</td></tr></tbody></table><table-wrap-foot><fn><p>* The first ipilimumab melanoma PIP, EMEA-000117-PIP02-10 is retrievable through the EMA document library [<xref rid="B31-children-05-00043" ref-type="bibr">31</xref>]. Its current version M07 (7th modification) can be retrieved through Google. ** PIPs later changed into waivers (no pediatric studies required). Original PIPs can be retrieved by the EMA document library, the respective link is referenced; current PIP versions can be googled by its respective number.</p></fn></table-wrap-foot></table-wrap><table-wrap id="children-05-00043-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">children-05-00043-t002_Table 2</object-id><label>Table 2</label><caption><p>First two ipilimumab Written Requested (WR) clinical studies.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><list list-type="order"><list-item><p>An open label, dose-escalation study of ipilimumab in pediatric patients (aged 1&#x02013;21 years) with refractory cancers.</p></list-item><list-item><p>A clinical study of ipilimumab in pediatric patients (12&#x02013;&#x0003c;18 years) with unresectable or metastatic melanoma to evaluate PK and safety.
<list list-type="bullet"><list-item><p>Efficacy in adolescent patients (12&#x02013;&#x0003c;18 years) will be determined by extrapolation from results observed in adult patients treated with ipilimumab for unresectable or metastatic melanoma.</p></list-item></list></p></list-item></list></td></tr></tbody></table></table-wrap><table-wrap id="children-05-00043-t003" orientation="portrait" position="float"><object-id pub-id-type="pii">children-05-00043-t003_Table 3</object-id><label>Table 3</label><caption><p>Terminated industry-sponsored international studies in adolescents with melanoma.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study #</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Abbreviated Study Description</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Centers</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sponsor</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pts</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Age (y)</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PIP/WR</th></tr></thead><tbody><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">NCT01519323</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Vemurafenib in Stage IIIC/IV Melanoma with BRAFV600 Mutations</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">26</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Roche</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">6</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">12&#x02013;17</td><td align="left" valign="middle" rowspan="1" colspan="1">EMEA-000978-PIP01-10 [<xref rid="B34-children-05-00043" ref-type="bibr">34</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EMEA-000978-PIP01-10-M01</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">NCT01696045</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Ipilimumab in untreated or previously treated advanced or metastatic melanoma.</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">32</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">BMS</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">12</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">12&#x02013;17</td><td align="left" valign="middle" rowspan="1" colspan="1">EMEA-000117-PIP02-10 (Original) [<xref rid="B31-children-05-00043" ref-type="bibr">31</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EMEA-000117-PIP02-10-M07 (current) WR [<xref rid="B37-children-05-00043" ref-type="bibr">37</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: Pts&#x02014;patients; Roche&#x02014;Hoffman-La Roche; BMS&#x02014;Bristol-Myers Squibb; y&#x02014;years.</p></fn></table-wrap-foot></table-wrap><table-wrap id="children-05-00043-t004" orientation="portrait" position="float"><object-id pub-id-type="pii">children-05-00043-t004_Table 4</object-id><label>Table 4</label><caption><p>Ongoing industry-sponsored pediatric studies including patients with melanoma.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study #</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Abbreviated Study Description</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Centers</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Age</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pts</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sponsor</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PIP #</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT02332668</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pembrulizumab in advanced melanoma or advanced R/R PDL1&#x02013;positive solid tumors or lymphoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6-month&#x02013;17 y</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">310</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MSD</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EMEA-001474-PIP01-13</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT01677741</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dabrafenib in advanced BRAF V600 mutation&#x02013;positive solid tumors</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1&#x02013;17 y</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">86</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GSK</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EMEA&#x02013;001147-PIP01-11-M03</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">NCT01962103</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Paclitaxel DF &#x00026; PE in R/R solid tumors</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">20</td><td align="left" valign="middle" rowspan="1" colspan="1">6-month&#x02013;17 y Ph1</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">107</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Celgene</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">EMEA-001308-PIP01-12</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2&#x02013;24 y Ph2</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">EUdraCT 2014-004685-25</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Cobimetinib DE, S &#x00026; PK in previously treated solid tumors </td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">41</td><td align="left" valign="middle" rowspan="1" colspan="1">1&#x02013;17 y (DES)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">50</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Roche</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">EMEA-001425-PIP01-13-M01</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6&#x02013;30 y (ES)</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">NCT02756845</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">S&#x00026;E of talimogene laherparepvec in melanoma and advanced non-CNS tumors</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">17</td><td align="left" valign="middle" rowspan="1" colspan="1">12&#x02013;21 y Ph1</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">18</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Amgen</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">EMEA-001251-PIP01-11-M03</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2&#x02013;11 y Ph2</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations in alphabetic order: CNS&#x02014;central nervous system; DE&#x02014;dose escalation; DES&#x02014;dose escalation study; DF&#x02014;dose finding; ES&#x02014;expansion study; GSK&#x02014;GlaxoSmithKline; MSD&#x02014;Merck, Sharp &#x00026; Dome; PE&#x02014;preliminary; Ph1&#x02014;phase 1; Ph2&#x02014;phase 2; PK&#x02014;pharmacokinetics efficacy; Pts&#x02014;Patients; Roche&#x02014;Hoffman-La Roche; R/R&#x02014;recurrent or refractory; S&#x02014;safety; y&#x02014;years.</p></fn></table-wrap-foot></table-wrap><table-wrap id="children-05-00043-t005" orientation="portrait" position="float"><object-id pub-id-type="pii">children-05-00043-t005_Table 5</object-id><label>Table 5</label><caption><p>Study centers of terminated and ongoing &#x0201c;pediatric&#x0201d; melanoma studies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study #</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Compound</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Centers</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT01519323</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Vemurafenib</bold></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">US: Los Angeles (CA), Aurora (CO), St. Peterburgh (FL), Bethesda (MD), Boston (MA), New York (NY), Memphis (TN), Houston (TX) &#x02022; Australia: Westmead, Brisbane &#x02022; France: Marseille, Pierre Benite &#x02022; Germany: Kiel, Mainz, Tuebingen &#x02022; Israel: Jerusalem, Petach-Tikva &#x02022; Italy: Roma, Genova, Milano &#x02022; Poland: Wroclaw &#x02022; Slovakia: Bratislava &#x02022; Spain: Esplugues De Llobregat-Barceona, Sevilla &#x02022; UK: Newcastle, Sutton</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT01696045</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Ipilimumab</bold></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">US: Phoenix (AZ), Los Angeles (CA), Orange (CA), Aurora (CO), Tampa (FL), Indianapolis (IN), Boston (MA), Rochester (MN), New York (NY), Pittsburg (PA), Memphis (TN), Houston (TX), 2 &#x000d7; Salt Lake City (UT) &#x02022; Belgium: Gent &#x02022; Denmark: Copenhagen &#x02022; France: Lyon, Marseille, Nantes, Villejuif Cedex &#x02022; Germany: Dortmund, Erlangen, Hamburg, 2 &#x000d7; Muenster &#x02022; Mexico: 2 &#x000d7; Mexico DF, Leon &#x02022; Spain: Esplugues de Llobregat-Barcelona &#x02022; UK: Bristol, Newcastle, Sutton</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT02332668</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Pembrulizumab</bold></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">US: Phoenix (AZ), Loma Linda (CA), 2 &#x000d7; Los Angeles (CA), Madera (CA), Orange (CA), San Diego (CA), San Francisco (CA), Aurora (CO), New Haven (CT), Washington DC, Atlanta (GA), Indianapolis (IN), Iowa City (IA), Boston (MA), Ann Arbor (MI), 2 &#x000d7; Minneapolis (MN), Cansas City (MO), Sant Louis (MO), New York (NY), Cincinatti (OH), Cleveland (OH), Columbus (OH), Philadelphia (PA), Pittsburg (PA), Memphis (TN), Nashville (TN), Dallas (TX), Fort Worth (TX), Houston (TX), Salt Lake City (UT), Seattle (WA), Milwaukee (WI) &#x02022; Australia: North Ride &#x02022; Brazil: Sao Paulo &#x02022; Canada: Kirkland &#x02022; France: Paris &#x02022; Germany: Haar &#x02022; Israel: Hod Hasharon &#x02022; Italy: Rome &#x02022; Korea: Seoul &#x02022; New Zealnd: Wellinton &#x02022; Sweden: Stockholm &#x02022; UK: Hoddesdon</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT01677741</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Dabrafenib</bold></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">US: Phoenix (AZ), Orange (CA), Baltimore (MD), Boston (MA), New York (NY), Cincinatti (OH), Memphis (TN), Seattle (WA) &#x02022; Australia: Parville, Subiaco &#x02022; Canada: Toronto &#x02022; Denmark: Copenhagen &#x02022; France: Marseille, Paris cedex 05, Paris cedex 12, Toulouse, Villejuif cedex &#x02022; Germany: Heidelberg, Regensburg, Berlin &#x02022; Israel: Jerusalem, Ramat-Gan &#x02022; Italy: Milano &#x02022; Spain: Esplugues de Llobregat-Barcelona, Madrid &#x02022; UK: Sutton, London</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT01962103</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Paclitaxel</bold></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">US: Phoenix (AZ), New York (NY) &#x02022; Canada: Ontario &#x02022; France: Lyon, Nancy, Paris, Villejuif &#x02022; Italy: Firenze, Genova, Milano, Padvoa, Rome, Torino &#x02022; Spain: 2 &#x000d7; Barcelona, Madrid, Sevilla, Valencia &#x02022; Switzerland: Zuerich &#x02022; UK: Sutton</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EUdraCT 2014-004685-25 *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Cobimetinib</bold></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Netherlands &#x02022; Ireland &#x02022; Denmark &#x02022; UK &#x02022; Germany &#x02022; Spain</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT02756845</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><bold>Talimogene laherparepvec</bold></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">US: Wilmington (DE), Chicago (IL), Indianapolis (IN), Detroit (MI), NY (NY), Cincinatti (OH), Columbus (OH) &#x02022; Canada: Montreal &#x02022; France: Lyon, Marseille, Paris &#x02022; Spain: Barcelona, Esplugues de Llobregat, Valenica, Madrid &#x02022; Switzerland: Basel, Zuerich</td></tr></tbody></table><table-wrap-foot><fn><p>Explanations: Abbreviations for US states by two-letter codes of the US Postal Service. * <uri xlink:href="www.clinicaltrialsregister.eu">www.clinicaltrialsregister.eu</uri> (EUdraCT) only lists countries, not individual study centers.</p></fn></table-wrap-foot></table-wrap></floats-group></article>